OncoSec Medical Inc Stock Nasdaq
Equities
US68234L2079
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 28.35M |
---|---|---|---|---|---|
Net income 2021 | -45M | Net income 2022 | -34M | EV / Sales 2021 | - |
Net cash position 2021 | 33.63M | Net cash position 2022 | 1.12M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.59
x | P/E ratio 2022 |
-0.83
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.57% |
Managers | Title | Age | Since |
---|---|---|---|
David Canton
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Sandra Aung
PRN | Corporate Officer/Principal | - | 20-10-11 |
Bridget O'Keeffe
PRN | Corporate Officer/Principal | - | 21-02-17 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+48.15% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |